Haiying Wang1, Zhengwei Wan1, Ru Xu2, Yujuan Guan3, Naling Zhu1, Jianping Li3, Zhiwei Xie3, Aiqi Lu3, Fuchun Zhang3, Yongshui Fu2, Shixing Tang1. 1. Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Epidemiology, School of Public Health, Southern Medical University. 2. Guangzhou Blood Center, Guangzhou, Guangdong, China. 3. Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Abstract
Background: Human pegivirus type 2 (HPgV-2) is a novel blood-borne human pegivirus that mainly infects hepatitis C virus (HCV)-infected subjects. We have investigated the prevalence of HPgV-2 in China, its association with HCV and human immunodeficiency virus type 1 (HIV-1), and the impact on HCV viral load and liver damage. Methods: A cross-sectional study was conducted with both blood donors and HCV- and HIV-1-infected patients in Guangzhou, China. All subjects were screened for anti-HPgV-2 and HPgV-2 RNA. Demographic and clinical information were obtained from electronic medical records. Results: We tested 8198 serum or plasma samples. Only 0.15% (6/4017) of healthy blood donors were positive for anti-HPgV-2 and negative for HPgV-2 RNA. No HPgV-2 viremia was detected in hepatitis B virus- or HIV-1-monoinfected individuals. The relatively high frequency of HPgV-2 infection was observed in 1.23% (30/2440) and 0.29% (7/2440) of HCV-infected persons by serological assay and reverse-transcription polymerase chain reaction, respectively. Furthermore, anti-HPgV-2 and HPgV-2 RNA were detected in 8.91% (18/202) and 3.47% (7/202), respectively, of HCV/HIV-1-coinfected subjects. HPgV-2 persistent infection was documented in about 30% of anti-HPgV-2-positive individuals. In addition, HPgV-2 infection may not affect HCV-related liver injury and HCV viral load. Conclusions: Our results indicate the rarity of HPgV-2 infection in the general population and tight association with HCV, in particular with HCV/HIV-1 coinfection. HPgV-2 appears not to worsen HCV-related liver damage. Our study provides new findings about the association of HPgV-2 and HCV/HIV-1 and the impact of HPgV-2 infection on HCV replication and pathogenesis.
Background: Human pegivirus type 2 (HPgV-2) is a novel blood-borne human pegivirus that mainly infects hepatitis C virus (HCV)-infected subjects. We have investigated the prevalence of HPgV-2 in China, its association with HCV and human immunodeficiency virus type 1 (HIV-1), and the impact on HCV viral load and liver damage. Methods: A cross-sectional study was conducted with both blood donors and HCV- and HIV-1-infectedpatients in Guangzhou, China. All subjects were screened for anti-HPgV-2 and HPgV-2 RNA. Demographic and clinical information were obtained from electronic medical records. Results: We tested 8198 serum or plasma samples. Only 0.15% (6/4017) of healthy blood donors were positive for anti-HPgV-2 and negative for HPgV-2 RNA. No HPgV-2 viremia was detected in hepatitis B virus- or HIV-1-monoinfected individuals. The relatively high frequency of HPgV-2 infection was observed in 1.23% (30/2440) and 0.29% (7/2440) of HCV-infectedpersons by serological assay and reverse-transcription polymerase chain reaction, respectively. Furthermore, anti-HPgV-2 and HPgV-2 RNA were detected in 8.91% (18/202) and 3.47% (7/202), respectively, of HCV/HIV-1-coinfected subjects. HPgV-2 persistent infection was documented in about 30% of anti-HPgV-2-positive individuals. In addition, HPgV-2 infection may not affect HCV-related liver injury and HCV viral load. Conclusions: Our results indicate the rarity of HPgV-2 infection in the general population and tight association with HCV, in particular with HCV/HIV-1 coinfection. HPgV-2 appears not to worsen HCV-related liver damage. Our study provides new findings about the association of HPgV-2 and HCV/HIV-1 and the impact of HPgV-2 infection on HCV replication and pathogenesis.
Authors: Angelo Fama; Melissa C Larson; Brian K Link; Thomas M Habermann; Andrew L Feldman; Timothy G Call; Stephen M Ansell; Mark Liebow; Jinhua Xiang; Matthew J Maurer; Susan L Slager; Grzegorz S Nowakowski; Jack T Stapleton; James R Cerhan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Anna Mrzljak; Irena Tabain; Hrvoje Premac; Maja Bogdanic; Ljubo Barbic; Vladimir Savic; Vladimir Stevanovic; Ana Jelic; Danko Mikulic; Tatjana Vilibic-Cavlek Journal: Curr Infect Dis Rep Date: 2019-11-21 Impact factor: 3.663
Authors: Nguyen To Anh; Nguyen Thi Thu Hong; Le Nguyen Truc Nhu; Tran Tan Thanh; Catherine Anscombe; Le Ngoc Chau; Tran Thi Thanh Thanh; Chuen-Yen Lau; Direk Limmathurotsakul; Nguyen Van Vinh Chau; H Rogier van Doorn; Xutao Deng; Motiur Rahman; Eric Delwart; Thuy Le; Guy Thwaites; Le Van Tan Journal: Emerg Infect Dis Date: 2018-11 Impact factor: 6.883
Authors: Siddharth Sridhar; Cyril C Y Yip; Nicholas F S Chew; Shusheng Wu; Kit-Hang Leung; Jasper F W Chan; Vincent C C Cheng; Kwok-Yung Yuen Journal: Open Forum Infect Dis Date: 2019-07-12 Impact factor: 3.835